LEADERSHIP

Mr. Stephan Jackman, Chief Executive Officer of Alzamend Neuro™, with over twenty years of multi-industry experience in administration, business and product development, marketing, project and program management, and strategic planning, provides a dynamic blend of bio-pharma experience and corporate leadership to navigate the challenges commonly faced by a developmental biotech company. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization with the dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals.

Mr. Henry Nisser, Esq., Executive Vice President, General Counsel and Corporate Secretary, has served Alzamend since May 1, 2019. From October 31, 2011 through April 26, 2019, Mr. Nisser was an associate and, subsequently, a partner with Sichenzia Ross Ference LLP (“SRF”), a law firm based in New York City.

While with SRF, his practice was concentrated in national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. Mr. Nisser drafted and negotiated a variety of agreements related to reorganizations, share and asset purchases, indentures, public and private offerings, tender offers and going private transactions. Mr. Nisser also represented clients’ special committees established to evaluate M&A transactions and advised such committees’ members with respect to their fiduciary duties.

Mr. Nisser is fluent in French and Swedish as well as conversant in Italian. Mr. Nisser received his B.A. from Connecticut College in 1992, where he majored in International Relations and Economics. He received his LLB from the University of Buckingham School of Law in 1999.

Mr. Ault founded Alzamend Neuro™, Inc., a biotechnology firm dedicated to finding the treatment, prevention and cure for Alzheimer’s Disease on February 26, 2016 and has served as its Chairman ever since.

Mr. Ault is a seasoned business professional and entrepreneur who has spent more than twenty-seven years identifying value in various financial markets including equities, fixed income, commodities, and real estate. On March 16, 2017, Mr. Ault was appointed Executive Chairman of the Board for DPW Holdings, Inc. (“DPW”), formerly known as Digital Power Corporation and on December 28, 2017,

Mr. Mansour the company’s former Chief Executive Officer and current member of the Board of Directors, has been leading the efforts to establish the Company, its Board of Directors, hire and contract with all appropriate FDA consulting firms, as well as establish and negotiate all relationships with the scientific and academic community.

Mr. Mansour has been actively involved with disruptive technologies as an inventor, manager, executive and coach for more than 3 decades. During that period, he has driven innovation and inspired collaboration among facilities in seven states and four continents. He is a master of operations, organizational change management, and integrations.

Dr. Thomas Wisniewski is a board-certified neurologist and neuropathologist and is the Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment. Dr. Wisniewski operates an active research laboratory focusing on neurodegenerative disorders with a particular focus on the mechanisms that drive amyloid deposition in Alzheimer’s and prion diseases. This work has led to over 300 peer-reviewed publications, 25 issued patents, and continuous funding from the NIH for over 26 years.